Key Highlights:
- Sun Pharma and LIB Therapeutics entered an exclusive licensing agreement for lerodalcibep, giving Sun Pharma rights to manufacture and commercialize the PCSK9 inhibitor globally, excluding the US and China.
- Lerodalcibep is a once-monthly PCSK9 inhibitor for lowering LDL-C in adults with hypercholesterolemia and mixed dyslipidemia. It is approved in the EU as Lyrokaul and in the US as Lerochol.
- Under the deal, LIB will receive upfront and milestone payments plus royalties on net sales. Sun Pharma will pursue regulatory approvals in additional licensed markets and expand access to the therapy.
Implications:
Sun Pharma has signed an exclusive global licensing deal (ex‑US and ex‑China) with LIB Therapeutics for lerodalcibep, a once‑monthly PCSK9 inhibitor for lowering LDL‑C in adults with hypercholesterolaemia/mixed dyslipidaemia. The drug is already approved in the EU as Lyrokaul (Sept 21, 2026) and in the U.S. as Lerochol. The deal gives Sun Pharma access to a fast‑growing ex‑US/China PCSK9 market estimated at ~$3.7 billion (global PCSK9 market approaching ~$7 billion in 2026), strengthening its innovative medicines portfolio beyond generics.
Source: Sun Pharma
